A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients

Stopped Further enrollment was halted in November 2021, enrolled subjects completed the study. Sponsor stopped further recruitment in this intravenous study to focus on intra-articular route of administration in subjects with tenosynovial giant cell tumor.

Conditions

• Tenosynovial Giant Cell Tumor
• Pigmented Villonodular Synovitis
• TGCT
• PVNS - Pigmented Villonodular Synovitis

Interventions

• BIOLOGICAL: AMB-05X

Sponsor

AmMax Bio, Inc.